Main	O
Outcomes	O
and	O
Measures	O
The	O
primary	O
end	O
point	O
was	O
organ	B-PrimaryOutcome
support	I-PrimaryOutcome
–	I-PrimaryOutcome
free	I-PrimaryOutcome
days	I-PrimaryOutcome
(	O
days	B-OutcomeDefinition
alive	I-OutcomeDefinition
and	I-OutcomeDefinition
free	I-OutcomeDefinition
of	I-OutcomeDefinition
ICU	I-OutcomeDefinition
-	I-OutcomeDefinition
based	I-OutcomeDefinition
respiratory	I-OutcomeDefinition
or	I-OutcomeDefinition
cardiovascular	I-OutcomeDefinition
support	I-OutcomeDefinition
)	O
within	B-TimeFrame
21	I-TimeFrame
days	I-TimeFrame
,	O
where	O
patients	O
who	O
died	O
were	O
assigned	O
–	O
1	O
day	O
.	O

The	O
primary	O
analysis	O
was	O
a	O
bayesian	O
cumulative	O
logistic	O
model	O
that	O
included	O
all	O
patients	O
enrolled	O
with	O
severe	O
COVID	O
-	O
19	O
,	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
site	O
,	O
region	O
,	O
time	O
,	O
assignment	O
to	O
interventions	O
within	O
other	O
domains	O
,	O
and	O
domain	O
and	O
intervention	O
eligibility	O
.	O

Superiority	O
was	O
defined	O
as	O
the	O
posterior	O
probability	O
of	O
an	O
odds	O
ratio	O
greater	O
than	O
1	O
(	O
threshold	O
for	O
trial	O
conclusion	O
of	O
superiority	O
>	O
99	O
%	O
)	O
.	O

Outcomes	O

The	O
primary	O
outcome	O
was	O
respiratory	O
and	O
cardiovascular	O
organ	O
support	O
–	O
free	O
days	O
up	O
to	O
day	O
21	O
,	O
an	O
ordinal	O
end	O
point	O
with	O
death	O
within	O
the	O
hospital	O
as	O
the	O
worst	O
outcome	O
(	O
labeled	O
–	O
1	O
)	O
,	O
then	O
the	O
length	O
of	O
time	O
free	O
of	O
both	O
respiratory	O
and	O
cardiovascular	O
organ	O
support	O
,	O
such	O
that	O
the	O
best	O
outcome	O
would	O
be	O
21	O
organ	O
support	O
–	O
free	O
days	O
.	O

Organ	O
support	O
was	O
defined	O
using	O
the	O
same	O
criteria	O
as	O
those	O
for	O
study	O
entry	O
.	O

This	O
outcome	O
was	O
used	O
in	O
a	O
recent	O
registration	O
trial	O
in	O
septic	O
shock	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
although	O
up	O
to	O
28	O
days	O
)	O
,	O
with	O
a	O
1	O
.	O
5	O
-	O
day	O
difference	O
(	O
7	O
.	O
5	O
%	O
-	O
15	O
%	O
relative	O
difference	O
)	O
considered	O
to	O
be	O
the	O
minimal	O
clinically	O
important	O
difference	O
.	O
18	O

Secondary	O
outcomes	O
were	O
in	B-SecondaryOutcome
-	I-SecondaryOutcome
hospital	I-SecondaryOutcome
mortality	I-SecondaryOutcome
,	O
ICU	B-SecondaryOutcome
and	I-SecondaryOutcome
hospital	I-SecondaryOutcome
length	I-SecondaryOutcome
of	I-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
respiratory	B-SecondaryOutcome
support	I-SecondaryOutcome
–	I-SecondaryOutcome
free	I-SecondaryOutcome
days	I-SecondaryOutcome
,	O
cardiovascular	B-SecondaryOutcome
organ	I-SecondaryOutcome
support	I-SecondaryOutcome
–	I-SecondaryOutcome
free	I-SecondaryOutcome
days	I-SecondaryOutcome
,	O
a	O
composite	O
outcome	O
of	O
progression	B-SecondaryOutcome
to	I-SecondaryOutcome
invasive	I-SecondaryOutcome
mechanical	I-SecondaryOutcome
ventilation	I-SecondaryOutcome
,	I-SecondaryOutcome
extracorporeal	I-SecondaryOutcome
membrane	I-SecondaryOutcome
oxygenation	I-SecondaryOutcome
(	I-SecondaryOutcome
ECMO	I-SecondaryOutcome
)	I-SecondaryOutcome
or	I-SecondaryOutcome
death	I-SecondaryOutcome
among	I-SecondaryOutcome
those	I-SecondaryOutcome
not	I-SecondaryOutcome
ventilated	I-SecondaryOutcome
at	I-SecondaryOutcome
baseline	I-SecondaryOutcome
,	O
and	O
the	O
WHO	B-SecondaryOutcome
ordinal	I-SecondaryOutcome
scale	I-SecondaryOutcome
(	O
range	O
,	O
0	O
-	O
8	O
,	O
where	O
0	O
=	O
no	O
illness	O
,	O
1	O
-	O
7	O
=	O
increasing	O
level	O
of	O
care	O
,	O
and	O
8	O
=	O
death	O
)	O
assessed	O
at	B-TimeFrame
day	I-TimeFrame
14	I-TimeFrame
.	I-TimeFrame
19	I-TimeFrame
,	I-TimeFrame
20	I-TimeFrame
This	O
scale	O
was	O
used	O
in	O
a	O
recent	O
COVID	O
-	O
19	O
RCT	O
of	O
remdesivir	O
,	O
where	O
an	O
odds	O
ratio	O
of	O
1	O
.	O
32	O
was	O
considered	O
clinically	O
important	O
,	O
although	O
few	O
data	O
support	O
that	O
assumption	O
.	O
20	O

